AMMONIUM CHLORIDE IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE IN PLASTIC CONTAINER (AMMONIUM CHLORIDE IN PLASTIC CONTAINER).

How it works

Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.

What the body does with it

Metabolism	Metabolized primarily in the liver via the urea cycle; ammonium ion is converted to urea, releasing hydrogen ions. The chloride ion is excreted renally.
Excretion	Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
Half-life	Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Protein binding	<1% bound to plasma proteins. Ammonium ions are primarily free in plasma.
Volume of Distribution	Approximately 0.2-0.3 L/kg, reflecting distribution mainly in extracellular fluid. Ammonium ions do not significantly penetrate cells under normal conditions.
Bioavailability	Oral: ~100% absorbed from the gastrointestinal tract, though first-pass hepatic metabolism (urea cycle) limits systemic availability of intact ammonium. Intravenous: 100% bioavailable.
Onset of Action	Oral: Onset of metabolic effect (acidification) occurs within 1-3 hours. Intravenous: Onset within 15-30 minutes when administered as a slow infusion for metabolic alkalosis.
Duration of Action	Duration of acidifying effect is approximately 4-6 hours after oral administration, dependent on renal function and acid-base status. For intravenous use, the effect subsides within 2-3 hours after cessation of infusion due to rapid conversion to urea.

Classification & Brands

Dosing & administration

For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min). For GFR 30-50 mL/min: reduce dose by 50% and monitor serum chloride and ammonia. For GFR >50 mL/min: no adjustment necessary.
Liver impairment	Contraindicated in severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class B: use with caution, reduce dose by 50% and monitor ammonia levels. For Child-Pugh class A: no adjustment necessary.
Pediatric use	For metabolic alkalosis: 50-100 mg/kg intravenously every 6-8 hours; maximum 2 g/day. For hypochloremic states: 75 mg/kg/day orally in divided doses.
Geriatric use	Start at lower end of dosing range (e.g., 1 g intravenously every 12 hours) due to age-related decline in renal function; monitor serum electrolytes and renal function closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE IN PLASTIC CONTAINER (AMMONIUM CHLORIDE IN PLASTIC CONTAINER).

Breastfeeding	No human data on excretion in breast milk. M/P ratio unknown. Caution advised; consider risk of infant acidosis and ammonia toxicity if exposed.
Teratogenic Risk	FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if maternal acidosis induced. Second/third trimester: may cause fetal acidosis, electrolyte disturbances, and potential for fetal harm if maternal overdose or pre-existing acidosis.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Severe hepatic insufficiency; severe renal failure with oliguria or anuria; primary respiratory acidosis; hypokalemia (due to risk of exacerbating potassium loss); hypersensitivity to ammonium chloride.

Clinical Precautions

Precautions	Use with caution in patients with hepatic impairment (risk of ammonia toxicity), renal dysfunction, or respiratory acidosis. Monitor acid-base status, serum chloride, and ammonia levels. Avoid rapid infusion to prevent severe acidosis. Not for use in severe hepatic insufficiency.
Food/Dietary	Avoid excessive dietary intake of chloride-rich foods (e.g., table salt, processed foods) as it may affect treatment. No specific food restrictions, but maintain balanced diet as advised by physician.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE IN PLASTIC CONTAINER (AMMONIUM CHLORIDE IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Metabolized primarily in the liver via the urea cycle; ammonium ion is converted to urea, releasing hydrogen ions. The chloride ion is excreted renally.
Excretion	Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
Half-life	Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Protein binding	<1% bound to plasma proteins. Ammonium ions are primarily free in plasma.
Volume of Distribution	Approximately 0.2-0.3 L/kg, reflecting distribution mainly in extracellular fluid. Ammonium ions do not significantly penetrate cells under normal conditions.
Bioavailability	Oral: ~100% absorbed from the gastrointestinal tract, though first-pass hepatic metabolism (urea cycle) limits systemic availability of intact ammonium. Intravenous: 100% bioavailable.
Onset of Action	Oral: Onset of metabolic effect (acidification) occurs within 1-3 hours. Intravenous: Onset within 15-30 minutes when administered as a slow infusion for metabolic alkalosis.
Duration of Action	Duration of acidifying effect is approximately 4-6 hours after oral administration, dependent on renal function and acid-base status. For intravenous use, the effect subsides within 2-3 hours after cessation of infusion due to rapid conversion to urea.

Classification & Brands

Dosing & administration

For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min). For GFR 30-50 mL/min: reduce dose by 50% and monitor serum chloride and ammonia. For GFR >50 mL/min: no adjustment necessary.
Liver impairment	Contraindicated in severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class B: use with caution, reduce dose by 50% and monitor ammonia levels. For Child-Pugh class A: no adjustment necessary.
Pediatric use	For metabolic alkalosis: 50-100 mg/kg intravenously every 6-8 hours; maximum 2 g/day. For hypochloremic states: 75 mg/kg/day orally in divided doses.
Geriatric use	Start at lower end of dosing range (e.g., 1 g intravenously every 12 hours) due to age-related decline in renal function; monitor serum electrolytes and renal function closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMMONIUM CHLORIDE IN PLASTIC CONTAINER (AMMONIUM CHLORIDE IN PLASTIC CONTAINER).

Breastfeeding	No human data on excretion in breast milk. M/P ratio unknown. Caution advised; consider risk of infant acidosis and ammonia toxicity if exposed.
Teratogenic Risk	FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if maternal acidosis induced. Second/third trimester: may cause fetal acidosis, electrolyte disturbances, and potential for fetal harm if maternal overdose or pre-existing acidosis.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Clinical Precautions

Precautions	Use with caution in patients with hepatic impairment (risk of ammonia toxicity), renal dysfunction, or respiratory acidosis. Monitor acid-base status, serum chloride, and ammonia levels. Avoid rapid infusion to prevent severe acidosis. Not for use in severe hepatic insufficiency.
Food/Dietary	Avoid excessive dietary intake of chloride-rich foods (e.g., table salt, processed foods) as it may affect treatment. No specific food restrictions, but maintain balanced diet as advised by physician.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	Ammonium chloride is used to treat severe metabolic alkalosis by providing chloride ions and generating mild metabolic acidosis. Monitor serum chloride, bicarbonate, and pH closely during infusion. Avoid in patients with severe hepatic impairment or renal failure. Infusion may cause local irritation; ensure proper IV access.
Patient Advice	This medication is used to correct an acid-base imbalance in your blood. · It will be given intravenously (IV) by a healthcare professional. · Report any burning, pain, or redness at the IV site immediately. · Do not consume large amounts of salt or salty foods unless directed. · Tell your doctor if you have liver or kidney disease.